Related references
Note: Only part of the references are listed.Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate
Ivana Rizzuto et al.
PHARMACOGENOMICS (2017)
A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours
B. Venugopal et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors
Sandrine J. Faivre et al.
INVESTIGATIONAL NEW DRUGS (2015)
Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer
Lucas de Sousa Cavalcante et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical Development
Magdalena Slusarczyk et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity
Elizabeth Poplin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer
Muhammad Saif et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2012)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Gemcitabine resistance in pancreatic cancer: Picking the key players
Michael P. Kim et al.
CLINICAL CANCER RESEARCH (2008)
Prolonged versus standard gemcitabine infusion: Translation of molecular pharmacology to new treatment strategy
Stephan A. Veltkamp et al.
ONCOLOGIST (2008)
Clinical phase I and pharmacology study of gemcitabine (2′,2′-difluorodeoxycytidine) administered in a two-weekly schedule
G. J. Peters et al.
JOURNAL OF CHEMOTHERAPY (2007)
Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry
S. A. Veltkamp et al.
JOURNAL OF MASS SPECTROMETRY (2006)
Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: Relationship to molecular mechanisms of gemcitabine resistance and survival
V Sebastiani et al.
CLINICAL CANCER RESEARCH (2006)
Pharmacokinetic evaluation of gemcitabine and 2 ',2 '-difluorodeoxycytidine-5 '-triphosphate after prolonged infusion in patients affected by different solid tumors
L. Cattel et al.
ANNALS OF ONCOLOGY (2006)
Mechanism for ribonucleotide reductase inactivation by the anticancer drug gemcitabine
S Pereira et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2004)
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma
J Spratlin et al.
CLINICAL CANCER RESEARCH (2004)
Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices
GH Lyman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)
AM Bergman et al.
DRUG RESISTANCE UPDATES (2002)
Confidence interval criteria for assessment of dose proportionality
BP Smith et al.
PHARMACEUTICAL RESEARCH (2000)
Share Paper
